Rosfjord et al., "The interaction of PKN3 with RhoC promotes malignant growth," Molecular Oncology, vol.
Traugott et al., "First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors," Journal of Clinical Oncology, vol.
The patent refers to the gene target PKN3
, protein kinase N beta, targeted by Silence's key development programme Atu027, a liposomal formulation in Phase I clinical development for systemic cancer indications.
More specifically, this new intellectual property covers the use of protein kinase N 3 (PKN3) for screening of therapeutic agents, thus preventing others from using PKN3 for screening purposes.
PKN3 is a protein kinase C-related molecule, involved in the PI3-kinase pathway that is believed to play an important role in the growth of cancer cells, as well as metastasis formation.
The EPO issued EP 1 536 827 B1, "Use Of Protein Kinase N Beta," which covers use of the protein Kinase N3 (PKN3) gene for drug-screening, diagnostic and therapeutic purposes.
This latest patent gives Silence an exclusive position not only with Atu027, but also with any siRNA or antisense molecule used to target PKN3 for the treatment of cancer and other diseases."
Atu027 is a proven inhibitor of the expression of PKN3
, a molecule that is believed to play an important role in the progression of cancer and metastasis formation in particular.